Follow-up in children with non-obese and non-autoimmune subclinical hypothyroidism

Zeynep Ergin1, Şenay Savaş-Erdeve2, Erdal Kurnaz2

  • 1Dr. Sami Ulus Obstetrics and Gynecology, Children's Health and Disease Training and Research Hospital, Pediatrics, Ankara, Turkey.

Insights

Subclinical hypothyroidism in children often resolves within a year without treatment. This study found no adverse effects on growth, blood pressure, or metabolic markers in pediatric patients during follow-up.

Area of Science:

  • Pediatric Endocrinology
  • Thyroid Disorders
  • Metabolic Health

Background:

  • Subclinical hypothyroidism (SCH) in children requires evaluation of clinical, laboratory, and imaging findings.
  • Understanding the clinical course of non-autoimmune SCH without goiter is crucial for management.

Purpose of the Study:

  • To assess clinical, laboratory, and imaging characteristics of pediatric subclinical hypothyroidism.
  • To determine the clinical course and outcomes of SCH in children over a one-year period.

Main Methods:

  • Inclusion of 25 children (ages 3-18) with non-autoimmune SCH, normal BMI, and no goiter.
  • Monitoring of thyroid-stimulating hormone (TSH), clinical parameters, and metabolic markers over 12 months.

Main Results:

  • A significant recovery rate of 73.7% was observed for subclinical hypothyroidism.
  • No significant changes in heart rate, diastolic blood pressure, lipid profile, glucose metabolism, or thyroid volume were noted.
  • Systolic blood pressure and high-sensitivity C-reactive protein (hs-CRP) showed transient increases but remained similar within the study group.

Conclusions:

  • Pediatric subclinical hypothyroidism generally does not progress to overt hypothyroidism within one year.
  • Untreated SCH in children showed no detrimental impact on height, BMI, blood pressure, or glucose and lipid metabolism during the follow-up period.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.8K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
265
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
302
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
285
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
189